Karyopharm Therapeutics (KPTI) Q1 2025 earnings summary

Executive summary

• Phase 3 SENTRY trial in JAKi-naïve myelofibrosis passed futility analysis and continues as planned, with enrollment expected to complete by June/July 2025 and top-line data anticipated late 2025/early 2026.

• Selinexor monotherapy in heavily pretreated myelofibrosis patients showed efficacy across key disease hallmarks, supporting potential for combination therapy.

• Commercial organization in multiple myeloma remains profitable and is positioned for rapid expansion into new indications if approved.

• Peak U.S. revenue potential for selinexor in myelofibrosis estimated at up to $1 billion.

• Demand for XPOVIO grew 5% year-over-year in Q1 2025, despite net product revenue being impacted by $5M in atypical returns of expired units.

Financial highlights

• Q1 2025 total revenue was $30.0M, down from $33.1M in Q1 2024; U.S. XPOVIO net product revenue was $21.1M, down from $26.0M year-over-year, impacted by a $5M increase in product return reserve.

• Royalty revenue grew 57% year-over-year to $1.7M, reflecting increased global demand.

• R&D expenses were $34.6M (down from $35.4M), and SG&A expenses were $27.4M (down from $29.5M), both reflecting cost optimization.

• Net loss for Q1 2025 was $23.5M ($2.77/share), improved from $37.4M ($4.85/share) in Q1 2024.

• Cash and investments at quarter-end were $70.3M, down from $109.1M at year-end 2024.

Outlook and guidance

• 2025 total revenue guidance is $140–$155M, with U.S. XPOVIO net product revenue expected at $115–$130M, now tracking toward the lower end due to Q1 returns.

• R&D and SG&A expenses projected at $240–$255M for 2025.

• Cash runway expected into early Q4 2025 after debt repayment and liquidity covenants; exploring options to extend runway.

• Preparing for commercial launch in myelofibrosis, pending positive SENTRY trial data and regulatory approval.

• Endometrial cancer and multiple myeloma programs continue to advance, with key data readouts anticipated in 2026.